AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through

HONG KONG, May 19, 2025 /PRNewswire/ -- While global giants like Moderna and BioNTech apply mRNA technology to broader disease markets, PRC's mRNA frontrunner is keeping pace. AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today that its self-developed mRNA shingles vaccine has received clinical trial approval from PRC's Center for Drug Evaluation (CDE), following its U.S. FDA clearance in March this year. The vaccine has demonstrated significantly stronger humoral and cellular immunity compared to international benchmark products.

AIM Vaccine's mRNA platform capabilities are once again in the spotlight. Fosun International Securities recently noted in a research report that AIM's mRNA shingles vaccine could challenge the existing market landscape with its potential for superior efficacy and safety.

Immunogenicity Indicators Significantly Outperform International Benchmarks

According to the announcement, preclinical trial results from third-party testing institutions demonstrate that AIM's mRNA shingles vaccine shows significantly higher specific T-cell immunity, specific IgG antibody titers, and membrane antigen fluorescent antibody (FAMA) titers compared to internationally marketed recombinant subunit control vaccines.

Furthermore, there are currently no mRNA-based shingles vaccines approved for marketing globally. According to recently published industry references, the vaccination rate for shingles vaccines among PRC's target population is less than 1%, indicating enormous growth potential.

Fosun International Securities' research report analysis mentions that as PRC's first company to establish a complete mRNA vaccine R&D system, its technological approach successfully avoids existing shingles vaccine patent barriers, creating favorable conditions for entering the global market projected to reach US$23.9 billion annually.

mRNA Platform Capabilities Continue to Lead the Industry

The competition in mRNA technology platforms between domestic and international companies has reached intensity comparable to an arms race, with infectious disease and cancer vaccines being the key battlegrounds. AIM Vaccine leads the industry through breakthrough progress in infectious disease vaccines.

Fosun International Securities' research report released in late March pointed out that AIM Vaccine holds a leading position in PRC's mRNA vaccine field, having obtained 11 clinical approvals across 6 countries, including 2 FDA approvals in the U.S. Its platform technology has been validated by favorable safety and efficacy clinical data from over 10,000 subjects. This latest approval for its mRNA shingles vaccine in PRC further highlights the company's leading position in next-generation vaccine technology and rapid commercialization potential.

Some industry observers believe that if PRC companies can continue to overcome core patents, expand indications, and deepen international cooperation, mRNA technology may become a hallmark area for PRC's biopharmaceutical industry to achieve technological leapfrogging.

In this cutting-edge field, AIM Vaccine has not only secured clinical approvals in both PRC and the U.S. for its mRNA shingles vaccine and mRNA RSV vaccine, but also has its next-generation mRNA rabies vaccine and mRNA influenza vaccine in pre-IND review and preclinical studies respectively, demonstrating the platform's strong extensibility and laying a solid foundation for sustained development and market leadership.

As analyzed by multiple investment institutions, AIM Vaccine combines innovative technology, industry leadership, and growth potential, making it a highly attractive investment choice. They remain optimistic about the company's development prospects driven by industry recovery and new products, and believe its valuation has significant upside potential.